Source link : https://newshealth.biz/health-news/adding-immunotherapy-based-combo-boosts-pfs-in-unresectable-liver-cancer/
CHICAGO — Combining standard transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), the phase III EMERALD-3 study showed. Median PFS was 13 months in patients who received a single dose of tremelimumab (Imjudo) and regular-interval durvalumab (Imfinzi), known as STRIDE, with lenvatinib (Lenvima) plus […]
The post Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-02 21:14:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8